+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuroendocrine Carcinoma"

From
From
Neuroendocrine Tumor Treatment Market Report 2026 - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Neuroendocrine Carcinoma Market Report 2026 - Product Thumbnail Image

Neuroendocrine Carcinoma Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Neuroendocrine Tumor Treatment Market in United States - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in United States

  • Report
  • February 2026
  • 150 Pages
  • United States
From
From
From
From
From
Radioligand Therapy Market - Global Forecast to 2036 - Product Thumbnail Image

Radioligand Therapy Market - Global Forecast to 2036

  • Report
  • September 2026
  • 321 Pages
  • Global
From
Somatostatin Analogs Market - Global Forecast 2026-2032 - Product Thumbnail Image

Somatostatin Analogs Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 184 Pages
  • Global
From
Stomach Cancer Treatment Market - Global Forecast 2026-2032 - Product Thumbnail Image

Stomach Cancer Treatment Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 186 Pages
  • Global
From
From
Manmade Version of Somatostatin Market - Global Forecast 2026-2032 - Product Thumbnail Image

Manmade Version of Somatostatin Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 182 Pages
  • Global
From
Lutetium-177 Market - Global Forecast 2026-2032 - Product Thumbnail Image

Lutetium-177 Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 193 Pages
  • Global
From
From
Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032 - Product Thumbnail Image

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 184 Pages
  • Global
From
From
Loading Indicator

Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence. The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more